Imlygic (talimogene laherparepvec): Special considerations to minimize the potential occurrence of adverse events in HSV-1 seronegative patients receiving vials from affected lots: Injections from Imlygic 106 PFU/mL vials from the affected lot numbers ...
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
Medicine name |
Imlygic
|
Active substance |
talimogene laherparepvec
|
Therapeutic area (MeSH) |
Melanoma
|
Procedure number |
EMEA/H/C/002771
|
Regulatory outcome |
Variation
|
DHPC type |
|
Human ATC code |
L01XX51
|
Dissemination date |
16/06/2022
|